Mechanistically, losartan can inhibit transforming growth factor beta (TGF-β) signaling – a pathway that promotes desmoplasia (fibrosis) and tumor progression – thereby reducing collagen I production and ECM density. Here, TGFB1 is linked to neoplasm.